AstraZeneca KK Of Japan Sees Benefits In Drug-Pricing Revision
This article was originally published in PharmAsia News
Executive Summary
The Japan arm of U.K.-based AstraZeneca is looking forward to a revision of Japan's drug-pricing system because AstraZeneca KK is likely to benefit